A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    59
    49
    Author
    Kelleher, AD; Puls, RL; Bebbington, M; Boyle, D; Ffrench, R; Kent, SJ; Kippax, S; Purcell, DFJ; Thomson, S; Wand, H; ...
    Date
    2006-01-09
    Source Title
    AIDS
    Publisher
    LIPPINCOTT WILLIAMS & WILKINS
    University of Melbourne Author/s
    Kent, Stephen; Purcell, Damian
    Affiliation
    Microbiology And Immunology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Kelleher, A. D., Puls, R. L., Bebbington, M., Boyle, D., Ffrench, R., Kent, S. J., Kippax, S., Purcell, D. F. J., Thomson, S., Wand, H., Cooper, D. A. & Emery, S. (2006). A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS, 20 (2), pp.294-297. https://doi.org/10.1097/01.aids.0000199819.40079.e9.
    Access Status
    This item is currently not available from this repository
    URI
    http://hdl.handle.net/11343/26433
    DOI
    10.1097/01.aids.0000199819.40079.e9
    Description

    C1 - Journal Articles Refereed
    Abstract
    An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 x 10(7) pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
    Keywords
    Medical Virology ; Infectious Diseases

    Export Reference in RIS Format     

    Collections